{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"971"},{"groupId":"OG001","value":"301"}],"units":"Participants"}],"description":"A serious adverse event (SAE) included a death which resulted in the participant discontinuing the study, a serious adverse experience that was considered by an investigator who was a qualified physician to be possibly, probably, or definitely vaccine related or study procedure related. Per protocol, the extension study included data from 9- to 15-year-old females regardless of lot administered.","groups":[{"description":"In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2).","id":"OG000","title":"Extension Study: 9- to 15-Year-Old Females"},{"description":"In the base study, participants received the 9vHPV L1 VLP vaccine (0.5 mL intramuscular injection) at Day 1, Month 2, and Month 6 and were evaluated through Month 12. In the extension studies, the participants were followed up for safety and immunogenicity up to Month 36 (EXT1) and for immunogenicity, effectiveness, and safety up to Month 126 (EXT2)","id":"OG001","title":"Extension Study: 9- to 15-Year-Old Males"}],"paramType":"NUMBER","populationDescription":"All participants who received at least 1 study vaccination in the base study and had follow-up data.","reportingStatus":"POSTED","timeFrame":"Up to ~Month 126","title":"Extension Study: Percentage of Participants With Vaccine-Related or Procedure-Related Serious Adverse Events","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}